Independent investing research and personal finance for IrelandUnderstand. Decide. Compound.

Health4 min read

What is orforglipron? How the Foundayo GLP-1 tablet works

How the Foundayo tablet activates the GLP-1 receptor, what the trials tested and what is known about access in Ireland.

Laboratory testing during orforglipron tablet manufacturingHealth / The Compound journal

Photo: Eli Lilly and Company · Foundayo press kit · cropped · Illustrative image.

Orforglipron is the active ingredient in Foundayo, a daily prescription tablet that activates the GLP-1 receptor. On 15 October 2026, the European Medicines Agency’s medicines committee recommended EU authorisation for weight management and type 2 diabetes in eligible adults. As of 19 November, we could verify that recommendation. We could not verify a final European Commission authorisation, a launch in the Republic of Ireland or HSE reimbursement. EMA assessment · European Commission register

The Science Behind the Drug

GLP-1 is a hormone the gut releases after eating. Orforglipron is a GLP-1 receptor agonist. When it activates this receptor, it increases insulin release when glucose is raised and reduces glucagon, a hormone that can raise blood glucose. It also reduces appetite and can slow stomach emptying. These effects involve the same receptor in different parts of the body. EMA mechanism overview · FDA prescribing information, section 12

Orforglipron is a small, non-peptide molecule. Semaglutide is a peptide whose tablet formulation includes an ingredient to help it cross the stomach lining. This matters for day-to-day use because the US Foundayo label allows it with or without food, while EU oral semaglutide product information calls for fasting. FDA prescribing information · EMA Wegovy product information, sections 4.2 and 5.2

What did the trials compare?

ATTAIN-1 compared orforglipron with placebo over 72 weeks in adults with obesity, or overweight with a related condition, who did not have diabetes. ACHIEVE-3 compared it with oral semaglutide in adults with type 2 diabetes whose blood glucose remained above target on metformin. In ACHIEVE-3, the orforglipron groups had larger reductions in HbA1c, a measure of average blood glucose, at 52 weeks than the corresponding oral semaglutide groups. ACHIEVE-3 tested diabetes treatment using oral semaglutide diabetes doses. The trial leaves open how Foundayo compares directly with the Wegovy tablet used for weight management. ATTAIN-1 · ACHIEVE-3 · EMA evidence summary

Which decisions apply where?

Jurisdiction Verified decision as of 19 November 2026
United States FDA authorised Foundayo for weight management in eligible adults in April 2026.
United Kingdom MHRA authorised it for weight management and type 2 diabetes in eligible adults in August 2026.
European Union EMA committee recommended authorisation for both uses in October 2026. A final Commission decision was unverified.

A decision in the UK or US does not establish access in the Republic of Ireland. EU authorisation, Irish launch and HSE reimbursement are separate milestones. US FDA · UK MHRA · EMA recommendation

What are the important safety questions?

The EMA identified nausea, vomiting and diarrhoea among the most common side effects. Severe or persistent abdominal pain, sometimes spreading to the back, needs urgent medical assessment because pancreatitis is a possible cause. The US label also flags interactions and precautions involving oral contraception, certain diabetes medicines, pregnancy and procedures under general anaesthesia or deep sedation. Discuss these situations with your care team using the product information for your jurisdiction. EMA safety summary · FDA prescribing information

What tablet absorption changes for the reader

Orforglipron is a small molecule and activates the GLP-1 receptor after being absorbed. It does not use the same absorption-enhancing formulation as oral semaglutide. An oral product’s directions can depend on how it gets into the circulation, so use the product information for the country and exact product concerned. You cannot infer the instructions for one tablet from another that acts on the same receptor. FDA Foundayo label · EMA Wegovy information

Separating comparisons from claims about which medicine to choose

In the ACHIEVE-3 comparison, both populations and treatment had defined entry rules, including type 2 diabetes and background metformin. The researchers followed blood glucose outcomes at specified doses. The trial cannot by itself show how orforglipron compares with oral Wegovy for weight management. For that question, look for a direct comparison in the population and formulations you are interested in. ACHIEVE-3 trial

Before discussing a future prescription in Ireland, note what you would want explained: the indication, local availability, how the treatment is reviewed, and what to do if vomiting affects fluid intake. Bring any contraception, diabetes treatment and planned procedures to the discussion. FDA Foundayo label

Cover photograph from Eli Lilly’s Foundayo digital media kit for press use, showing manufacturing laboratory testing.

YOUR PRIVACY

Help us understand what gets read.

With your permission, anonymous Google Analytics measurements tell us which articles are useful. We do not send calculator entries or form values. You can decline and still read everything.